With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Soon entering Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.


Press Releases

Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study

Crinetics lead ACTH antagonist CRN04894 enters Phase 1 study to assess suppression of cortisol, cortisol precursors and adrenal androgens after ACTH stimulation.

Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study

CRN04777, an oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism (congenital HI) has advanced into Phase 1 study.

Corporate Presentation

Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.